Is Hinge Health Inc (HNGE) a risky stock?
As of July 23, 2026, Clavix grades Hinge Health Inc (HNGE) B- for risk, a composite score of 65 out of 100 on an A+ to F scale, which puts HNGE in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 23, 2026. Clavix regrades every trading day.
The five risk dimensions behind HNGE's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how HNGE scores on each, as of July 23, 2026.
What's moving HNGE's risk right now
Company-specific signals Clavix flags behind HNGE's current grade, drawn from recent news and filings as of July 23, 2026.
The insider sale represents profit-taking after a substantial stock rally, but the retention of 12.2 million derivative securities signals continued long-term confidence in Hinge…
Raised guidance reduces near-term uncertainty and is often a leading indicator of further upward estimate revisions.
Earnings are roughly in line with expectations, providing little catalyst in either direction.
Recent HNGE news
The latest headlines Clavix ingested for Hinge Health Inc, newest first. These feed the news-sentiment dimension of HNGE's grade.
-
Canaccord Genuity Group raised its price target on Hinge Health (NYSE:HNGE) from $76.00 to $100.00 and assigned a 'buy' rating in a research report.
What a B- grade means
On the Clavix A+ to F scale, HNGE's composite of 65 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell HNGE or any security. Grades are risk indicators, not predictions of return. Data may be delayed.